2-(8-Ethyl-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-7-ylthio)-N-o-tolylacetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-(8-Ethyl-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-7-ylthio)-N-o-tolylacetamide
• 英文别名: 2-[(8-ethyl-2,3-dihydro-[1,4]dioxino[2,3-g]quinolin-7-yl)sulfanyl]-N-(2-methylphenyl)acetamide
• 化学式: C₂₂H₂₂N₂O₃S
• 分子量: 394.5
• InChiKey: WOPFGLSZCHHFIM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  85.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE<br/>[FR] NOUVEAUX INHIBITEURS DE KINASE PRÉSENTANT UNE ACTIVITÉ ANTICANCÉREUSE ET LEUR PROCÉDÉ D'UTILISATION
  申请人：ALLCRON PHARMA INC

  公开号：WO2019182944A1

  公开（公告）日：2019-09-26

  Pharmaceutical compositions of the invention comprise kinase inhibitors having a disease-modifying action in the treatment of diseases associated with BCR-ABL activity that include cancer, including chronic myeloid leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, lymphomas, and metastatic carcinoma.

  本发明的药物组合物包括激酶抑制剂，在治疗与BCR-ABL活性相关的疾病中具有疾病修正作用，包括癌症，包括慢性髓细胞白血病、急性淋巴细胞白血病、急性髓细胞白血病、慢性淋巴细胞白血病、多发性骨髓瘤、淋巴瘤和转移性癌症。
• Kinase inhibitors
  申请人：Rajasekaran Ayyappan K.

  公开号：US10639304B2

  公开（公告）日：2020-05-05

  The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.

  所公开的分子是 Bcr-Abl 和 Src 激酶的抑制剂。这些分子对格列卫耐药细胞具有细胞毒性。Bcr-Abl 和 Src 激酶抑制剂可用于治疗慢性骨髓性白血病等疾病。
• KINASE INHIBITORS
  申请人：Rajasekaran Ayyappan K.

  公开号：US20150140071A1

  公开（公告）日：2015-05-21

  The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.
• Kinase Inhibitors
  申请人：Rajasekaran Ayyappan K.

  公开号：US20170231975A1

  公开（公告）日：2017-08-17

  The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.
• NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE
  申请人：ALLCRON PHARMA INC.

  公开号：US20210040104A1

  公开（公告）日：2021-02-11

  Pharmaceutical compositions of the invention comprise kinase inhibitors having a disease-modifying action in the treatment of diseases associated with BCR-ABL activity that include cancer, including chronic myeloid leukemia, acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, lymphomas, and metastatic carcinoma.